Journal of Stem Cell Research & Therapy

Advancements in Stem Cell-Derived Therapies for Intestinal Preservation and Repair

Edward M Johnson^* Department of Medicine, Institute of Genetics and Molecular Medicine, Western General Hospital University of Edinburgh, Edinburgh, United Kingdom
^*Correspondence: Edward M Johnson, Department of Medicine, Institute of Genetics and Molecular Medicine, Western General Hospital University of Edinburgh, Edinburgh, United Kingdom, Email:

Received: 23-Feb-2024, Manuscript No. JSCRT-24-25296; Editor assigned: 26-Feb-2024, Pre QC No. JSCRT-24-25296 (PQ); Reviewed: 11-Mar-2024, QC No. JSCRT-24-25296; Revised: 18-Mar-2024, Manuscript No. JSCRT-24-25296 (R); Published: 25-Mar-2024, DOI: 10.35248/2157-7633.24.14.629

Description

The human intestine is a remarkable organ critical for nutrient absorption and immune function. However, disorders affecting its development or integrity pose significant challenges, particularly in pediatric patients. Traditional treatments often fall short in providing long-term solutions. In recent years, remarkable progress has been made in controlling the regenerative potential of stem cells to address these challenges. This article explores the potential region of stem cell-derived therapies aimed at preserving and repairing the developing intestine in pediatric patients.

Intestinal disorders in pediatrics

Pediatric intestinal disorders encompass a broad spectrum of conditions, ranging from congenital anomalies like Hirschsprung's disease to Inflammatory Bowel Diseases (IBD) such as Crohn's disease and ulcerative colitis. These disorders can lead to malabsorption, impaired growth, and compromised quality of life for affected children. Current treatments often involve surgery, medication, or dietary interventions, which may offer symptomatic relief but frequently fail to address the underlying issues effectively [1,2].

The potential of stem cell-derived therapies

Stem cells hold tremendous potential in regenerative medicine due to their unique ability to differentiate into various cell types and repair damaged tissues. In the context of pediatric intestinal disorders, stem cell-derived therapies offer novel approaches for tissue repair and regeneration. These therapies can be broadly categorized into two main strategies: Stem cell transplantation and tissue engineering.

Stem cell transplantation: Stem cell transplantation involves introducing exogenous stem cells into the damaged intestine to facilitate repair and regeneration. Mesenchymal Stem Cells (MSCs), derived from sources such as bone marrow or umbilical cord tissue, have shown particular promise in preclinical and clinical studies. MSCs possess immunomodulatory properties and can promote tissue healing through paracrine signaling and differentiation into supportive cell types [3].

Recent advancements in stem cell transplantation have focused on optimizing delivery methods and enhancing therapeutic efficacy. Techniques such as tissue engineering scaffolds and microencapsulation have been explored to improve cell engraftment and survival within the intestinal microenvironment. Additionally, genetic engineering approaches enable the modification of stem cells to enhance their regenerative potential or target specific disease mechanisms, further enhancing the therapeutic outcome [4,5].

Tissue engineering: Tissue engineering strategies involve creating functional intestinal tissue ex vivo for transplantation or in situ regeneration within the body. These approaches typically utilize a combination of stem cells, biomaterial scaffolds, and growth factors to represent the native intestinal architecture and promote tissue integration and functionality.

One potential approach involves the generation of intestinal organoids from Pluripotent Stem Cells (PSCs) or adult tissue derived stem cells. Intestinal organoids are three-dimensional structures that recapitulate main features of the intestinal epithelium, including crypt-villus architecture and cellular diversity. These organoids can serve as models for studying disease mechanisms, drug screening, and potentially as a source of transplantable tissue for patients with intestinal disorders [6,7].

In addition to organoids, researchers are exploring bioengineered scaffolds seeded with patient-derived stem cells to facilitate in situ tissue regeneration. These scaffolds provide a supportive microenvironment for cell growth and differentiation, promoting the formation of functional intestinal tissue. By customizing scaffold properties such as stiffness, porosity, and bioactive molecule incorporation, researchers can optimize tissue regeneration outcomes [8-10].

Challenges and future directions

Despite the potential advancements in stem cell-derived therapies for pediatric intestinal disorders, several challenges remain. These include optimizing cell survival and engraftment, ensuring long-term functionality and safety, and addressing immune rejection concerns. Moreover, the translation of these therapies from preclinical studies to clinical practice requires rigorous evaluation through well-designed clinical trials.

Looking ahead, ongoing research efforts aim to overcome these challenges and further enhance the therapeutic potential of stem cell-derived therapies for intestinal preservation and repair. This includes refining cell manufacturing techniques, improving transplantation methods, and developing strategies to mitigate immune responses. Collaborative initiatives involving multidisciplinary teams of scientists, clinicians, and industry partners will be important in driving these advancements forward.

Conclusion

Stem cell-derived therapies hold significant potential for revolutionizing the management of pediatric intestinal disorders. By controlling the regenerative potential of stem cells, researchers are preparing for innovative approaches to preserve and repair the developing intestine. While challenges remain, continued investment in research and clinical translation efforts will ultimately benefit pediatric patients by offering more effective and sustainable treatment options.

References

1. Nagaishi K, Arimura Y, Fujimiya M. Stem cell therapy for inflammatory bowel disease. J Gastroenterol. 2015;50:280-286.

   [Crossref] [Google Scholar] [PubMed]

2. Finkbeiner SR, Freeman JJ, Wieck MM, El-Nachef W, Altheim CH, Tsai YH, et al. Generation of tissue-engineered small intestine using embryonic stem cell-derived human intestinal organoids. Biol Open. 2015;4(11):1462-1472.

   [Crossref] [Google Scholar] [PubMed]

3. Hierlmeier S, Eyrich M, Wölfl M, Schlegel PG, Wiegering V. Early and late complications following hematopoietic stem cell transplantation in pediatric patients–A retrospective analysis over 11 years. PloS One. 2018;13(10):e0204914.

   [Crossref] [Google Scholar] [PubMed]

4. Algeri M, Merli P, Locatelli F, Pagliara D. The role of allogeneic hematopoietic stem cell transplantation in pediatric leukemia. J Clin Med. 2021;10(17):3790.

   [Crossref] [Google Scholar] [PubMed]

5. Merli P, Algeri M, Del Bufalo F, Locatelli F. Hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2019;14:94-105.

   [Crossref] [Google Scholar] [PubMed]

6. Bonis V, Rossell C, Gehart H. The intestinal epithelium–fluid fate and rigid structure from crypt bottom to villus tip. Front Cell Dev Biol. 2021;9:661931.

   [Crossref] [Google Scholar] [PubMed]

7. Rudolph SE, Longo BN, Tse MW, Houchin MR, Shokoufandeh MM, Chen Y, et al. Crypt-villus scaffold architecture for bioengineering functional human intestinal epithelium. ACS Biomater Sci Eng. 2022;8(11):4942-4955.

   [Crossref] [Google Scholar] [PubMed]

8. García-García A, Klein T, Born G, Hilpert M, Scherberich A, Lengerke C, et al. Culturing patient-derived malignant hematopoietic stem cells in engineered and fully humanized 3D niches. Proc Natl Acad Sci U S A. 2021;118(40):e2114227118.

   [Crossref] [Google Scholar] [PubMed]

9. Wagner DE, Bonvillain RW, Jensen T, Girard ED, Bunnell BA, Finck CM, et al. Can stem cells be used to generate new lungs? Ex vivo lung bioengineering with decellularized whole lung scaffolds. Respirology. 2013;18(6):895-911.

   [Crossref] [Google Scholar] [PubMed]

10. Brännström M, Hellström M. Prospects for use of bioengineered tissue from stem cells in gynecology. Acta Obstet Gynecol Scand. 2023;102(7):808-810.

    [Crossref] [Google Scholar] [PubMed]